MORRISVILLE, NC – King Street Properties announced today that Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, signed a lease for approximately 70,000 square feet at King Street’s Pathway Triangle in North Carolina’s Research Triangle.
“We’re excited to welcome Liquidia to Pathway Triangle. Their decision to grow on our campus reinforces the strength of the Research Triangle as a hub for life science innovation,” said Sara McTyeire, Managing Director, King Street Properties. “We’re proud to offer the kind of flexible, high-quality space for biomanufacturing and advanced manufacturing companies that support pivotal moments in their growth.”
“Liquidia is proud to collaborate with King Street Properties, one of the nation’s premier life science developers, as we expand our manufacturing footprint in North Carolina,” said Michael Hunter, SVP of Manufacturing Operations at Liquidia. “This strategic partnership reinforces our commitment to addressing the unmet needs of pulmonary hypertension patients and positions us to meet the growing demand in this rapidly evolving market.”
Beginning in 2026, Liquidia will expand its manufacturing operations at Pathway Triangle on the heels of the FDA approval it received last month for its YUTREPIA™ (treprostinil) inhalation powder. Liquidia will occupy Building One at 1000 Science Drive.
Pathway Triangle is a 1 million square foot purpose-built development by King Street, designed to remove the real estate obstacles for life science companies and shorten their time to occupancy by 18-24 months. Phase 1 of Pathway Triangle has been completed and just a few weeks ago, the team broke ground on an exclusive tenant amenity center called ‘The Junction,’ which will offer a curated list of offerings from meeting and conference space to fitness and dining.
King Street has successfully launched the Pathway platform in Devens, Massachusetts and in the Research Triangle in North Carolina.